8 July 2021 LungLife AI, Inc. ("LungLife" or the "Company") Director/PDMR Notification LungLife (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that it has been notified of the following transaction in the Company's common shares of US $0.0001 each (“Common Shares”) undertaken by directors. The transactions were […]
LungLife AI licensure/accreditation information posted here.